Loading stock data…
KIDS
$15.63+0.57 (+3.78%)
Market ClosedLast close May 1
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OrthoPediatrics Corp. in the Healthcare sector is trading at $15.63. The stock is currently near its 52-week low of $14.42, remaining 13.6% below its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why KIDS maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$15.63
Potential Upside
5%
Whystock Fair Value$16.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$25.00+59.9%
Range$20.00 – $34.00
Fundamentals
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$416.37M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.05%
Volume
Today's trading volume
386,972
Recent News
OrthoPediatrics Corp (KIDS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
OrthoPediatrics Corp (KIDS) reports a 13% revenue increase and raises 2026 guidance, while navigating weather impacts and cautious product launch timelines.
OrthoPediatrics (KIDS) Q1 2026 Earnings Transcript
During the call today, management will also discuss certain non-GAAP financial measures, which are supplemental measures of performance. For each non-GAAP financial measure referenced on this call, the company has included a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures in its first quarter earnings release. Please note that the non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for OrthoPediatrics Corp. financial results prepared in accordance with GAAP.
OrthoPediatrics Corp. Q1 2026 Earnings Call Summary
Moby summary of OrthoPediatrics Corp.'s Q1 2026 earnings call
OrthoPediatrics Q1 Earnings Call Highlights
OrthoPediatrics (NASDAQ:KIDS) opened 2026 with first-quarter revenue growth, improving profitability metrics, and what management described as early traction from a new wave of product launches. Executives emphasized patient impact as a core operating focus, noting the company supported the treatmen
OrthoPediatrics (KIDS) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for OrthoPediatrics (KIDS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.